Differences in cannabis-related experiences between patients with a first episode of psychosis and controls

Psychological Medicine

Volumn 46, Issue 5, 2016, Pages 995-1003

  Bianconi, F ^a   Bonomo, M ^a   Marconi, A ^b   Kolliakou, A ^a   Stilo, S A ^a   Iyegbe, C ^a   Gurillo Munoz P ^c   Homayoun, S ^a   Mondelli, V ^a   Luzi, S ^a   Dazzan, P ^a   Prata, D ^a,d   La Cascia, C ^e   O'Connor, J ^a   David, A ^a   Morgan, C ^a   Murray, R M ^a   Lynskey, M ^a   Di Forti, M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c HOSPITAL MARINA BAIXA   (Spain)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cannabis; Cannabis Experience Questionnaire; experiences; first episode of psychosis; psychosis

Indexed keywords

CANNABIS;

ADULT; ADVERSE EFFECTS; CANNABIS SMOKING; FEMALE; HUMAN; MALE; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; QUESTIONNAIRE; STATISTICAL MODEL; YOUNG ADULT;

ADULT; CANNABIS; FEMALE; HUMANS; LINEAR MODELS; MALE; MARIJUANA SMOKING; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84949807034     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291715002494     Document Type: Article

References (33)

1. Barkus EJ, Stirling J, Hopkins RS, Lewis S (2006). Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39, 175-178.
2. Casadio P, Fernandes C, Murray RM, Di Forti M (2011). Cannabis use in young people: the risk for schizophrenia. Neuroscience and Biobehavioral Reviews 35, 1779-1787.
3. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR, Handley R, Mondelli V, Dazzan P, Pariante C, David AS, Morgan C, Powell J, Murray RM (2012). Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological Psychiatry 72, 811-816.
4. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, Bianconi F, Gardner-Sood P, O'Connor J, Russo M, Stilo SA, Marques TR, Mondelli V, Dazzan P, Pariante C, David AS, Gaughran F, Atakan Z, Iyegbe C, Powell J, Morgan C, Lynskey M, Murray RM (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. Lancet Psychiatry 2, 233-238.
5. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM (2009). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry 195, 488-491.
6. Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaughran F, David AS, Morgan C, Stahl D, Khondoker M, MacCabe JH, Murray RM (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin 40, 1509-1517.
7. D'Souza DC (2007). Cannabinoids and psychosis. International Review of Neurobiology 78, 289-326.
8. D'Souza DC, Sewell RA, Ranganathan M (2009). Cannabis and psychosis/schizophrenia: human studies. European Archives of Psychiatry and Clinical Neuroscience 259, 413-431.
9. Fergusson DM, Horwood LJ, Swain-Campbell NR (2003). Cannabis dependence and psychotic symptoms in young people. Psychological Medicine 33, 15-21.
10. Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS (2015). The association between cannabis abuse and subsequent schizophrenia: A Swedish national co-relative control study. Psychological Medicine 45, 407-414.
11. Hardwick S, King L (2008). Home Office Cannabis Potency Study 2008. Home Office Scientific Development Branch: London.
12. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM (2008) Gene-environment interplay between cannabis and psychosis. Schizophrenia Bulletin 34, 1111-1121.
13. Henquet C, Murray RM, Linszen D, van Os J (2005). The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin 31, 608-612.
14. Kendler KS, Karkowski LM, Neale MC, Prescott CA (2000). Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Archives of General Psychiatry 57, 261-269.
15. Kendler KS, Ohlsson H, Maes HH, Sundquist K, Lichtenstein P, Sundquist J (2015). A population-based Swedish Twin and Sibling Study of cannabis, stimulant and sedative abuse in men. Drug and Alcohol Dependence 149, 49-54.
16. Kendler KS, Prescott CA (1998). Cannabis use, abuse, and dependence in a population-based sample of female twins. American Journal of Psychiatry 155, 1016-1022.
17. Khantzian EJ (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry 142, 1259-1264.
18. Kolliakou A, Castle D, Sallis H, Joseph C, O'Connor J, Wiffen B, Ismail K (2015). Reasons for cannabis use in first-episode psychosis: does strength of endorsement change over 12 months? European Psychiatry 30, 152-159.
19. Kolliakou A, Joseph C, Ismail K, Atakan Z, Murray RM (2011). Why do patients with psychosis use cannabis and are they ready to change their use? International Journal of Developmental Neuroscience 29, 335-346.
20. Lyons MJ, Toomey R, Meyer JM, Green AI, Eisen SA, Goldberg J, True WR, Tsuang MT (1997). How do genes influence marijuana use? The role of subjective effects. Addiction 92, 409-417.
21. Murray RM, Mehta M, Di Forti M (2014). Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis. Biological Psychiatry 75, 430-431.
22. Mwenda L, Ahmad M, Kumari K (2005). Seizures on Drugs in England and Wales, 2003. Findings 265. Home Office Research, Development and Statistics Directorate. Office for National Statistics: London.
23. Potter DJ, Clark P, Brown MB (2009). Potency of 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. Journal of Forensic Science 53, 90-94.
24. Radhakrishnan R, Wilkinson ST, D'Souza DC (2014). Gone to pot-A review of the association between cannabis and psychosis. Frontiers in Psychiatry 5, 54.
25. Thornton LK, Baker AL, Johnson MP, Kay-Lambkin F, Lewin TJ (2012). Reasons for substance use among people with psychotic disorders: method triangulation approach. Psychology of Addictive Behaviors 26, 279-288.
26. United Nations Office on Drugs and Crime (2014). World Drug Report 2014. United Nations publication, sales no. E. 14. XI. 7. United Nations: New York.
27. van der Meer FJ, Velthorst E; Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2015). Course of cannabis use and clinical outcome in patients with non-Affective psychosis: A 3-year follow-up study. Psychological Medicine 45, 1977-1988.
28. van Winkel R, van Beveren NJM, Simons C; Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011). AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology 36, 2529-2537.
29. Wetherill RR, Childress AR, Jagannathan K, Bender J, Young KA, Suh JJ, O'Brien CP, Franklin TR (2014). Neural responses to subliminally presented cannabis and other emotionally evocative cues in cannabis-dependent individuals. Psychopharmacology (Berlin) 231, 1397-1407.
30. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N (1990). SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 47, 589-593.
31. World Health Organization (1992) ICD-10 Classifications of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization: Geneva.
32. Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry 193, 357-363.
33. Zeiger JS, Haberstick BC, Corley RP, Ehringer MA, Crowley TJ, Hewitt JK, Hopfer CJ, Stallings MC, Young SE, Rhee SH (2012). Subjective effects for alcohol, tobacco, and marijuana association with cross-drug outcomes. Drug and Alcohol Dependence 123 (Suppl. 1), S52-S58.